Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Effective and safe tumor inhibition using vinblastine in medulloblastoma.

Nobre L, Pauck D, Golbourn B, Maue M, Bouffet E, Remke M, Ramaswamy V.

Pediatr Blood Cancer. 2019 Jun;66(6):e27694. doi: 10.1002/pbc.27694. Epub 2019 Mar 8.

PMID:
30848061
2.

Characterization of a Clival Chordoma Xenograft Model Reveals Tumor Genomic Instability.

Diaz RJ, Luck A, Bondoc A, Golbourn B, Picard D, Remke M, Loukides J, Sabha N, Smith C, Cusimano MD, Rutka JT.

Am J Pathol. 2018 Dec;188(12):2902-2911. doi: 10.1016/j.ajpath.2018.08.004. Epub 2018 Sep 22.

PMID:
30248342
3.

Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery.

Alli S, Figueiredo CA, Golbourn B, Sabha N, Wu MY, Bondoc A, Luck A, Coluccia D, Maslink C, Smith C, Wurdak H, Hynynen K, O'Reilly M, Rutka JT.

J Control Release. 2018 Jul 10;281:29-41. doi: 10.1016/j.jconrel.2018.05.005. Epub 2018 May 16.

4.

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.

Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez NR, Lu M, Chan TS, Picard D, de Antonellis P, Khuong-Quang DA, Planello AC, Zeller C, Barsyte-Lovejoy D, Lafay-Cousin L, Letourneau L, Bourgey M, Yu M, Gendoo DMA, Dzamba M, Barszczyk M, Medina T, Riemenschneider AN, Morrissy AS, Ra YS, Ramaswamy V, Remke M, Dunham CP, Yip S, Ng HK, Lu JQ, Mehta V, Albrecht S, Pimentel J, Chan JA, Somers GR, Faria CC, Roque L, Fouladi M, Hoffman LM, Moore AS, Wang Y, Choi SA, Hansford JR, Catchpoole D, Birks DK, Foreman NK, Strother D, Klekner A, Bognár L, Garami M, Hauser P, Hortobágyi T, Wilson B, Hukin J, Carret AS, Van Meter TE, Hwang EI, Gajjar A, Chiou SH, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat DD, Scheinemann K, Fleming AJ, Johnston DL, Michaud J, Zelcer S, Hammond R, Afzal S, Ramsay DA, Sirachainan N, Hongeng S, Larbcharoensub N, Grundy RG, Lulla RR, Fangusaro JR, Druker H, Bartels U, Grant R, Malkin D, McGlade CJ, Nicolaides T, Tihan T, Phillips J, Majewski J, Montpetit A, Bourque G, Bader GD, Reddy AT, Gillespie GY, Warmuth-Metz M, Rutkowski S, Tabori U, Lupien M, Brudno M, Schüller U, Pietsch T, Judkins AR, Hawkins CE, Bouffet E, Kim SK, Dirks PB, Taylor MD, Erdreich-Epstein A, Arrowsmith CH, De Carvalho DD, Rutka JT, Jabado N, Huang A.

Cancer Cell. 2016 Dec 12;30(6):891-908. doi: 10.1016/j.ccell.2016.11.003.

5.

Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.

Vartanian A, Agnihotri S, Wilson MR, Burrell KE, Tonge PD, Alamsahebpour A, Jalali S, Taccone MS, Mansouri S, Golbourn B, Aldape KD, Zadeh G.

Oncotarget. 2016 Oct 25;7(43):69518-69535. doi: 10.18632/oncotarget.11680.

6.

A role for activated Cdc42 in glioblastoma multiforme invasion.

Okura H, Golbourn BJ, Shahzad U, Agnihotri S, Sabha N, Krieger JR, Figueiredo CA, Chalil A, Landon-Brace N, Riemenschneider A, Arai H, Smith CA, Xu S, Kaluz S, Marcus AI, Van Meir EG, Rutka JT.

Oncotarget. 2016 Aug 30;7(35):56958-56975. doi: 10.18632/oncotarget.10925.

7.

PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma.

Agnihotri S, Golbourn B, Huang X, Remke M, Younger S, Cairns RA, Chalil A, Smith CA, Krumholtz SL, Mackenzie D, Rakopoulos P, Ramaswamy V, Taccone MS, Mischel PS, Fuller GN, Hawkins C, Stanford WL, Taylor MD, Zadeh G, Rutka JT.

Cancer Res. 2016 Aug 15;76(16):4708-19. doi: 10.1158/0008-5472.CAN-15-3079. Epub 2016 Jun 20.

8.

Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.

Chornenkyy Y, Agnihotri S, Yu M, Buczkowicz P, Rakopoulos P, Golbourn B, Garzia L, Siddaway R, Leung S, Rutka JT, Taylor MD, Dirks PB, Hawkins C.

Mol Cancer Ther. 2015 Nov;14(11):2560-8. doi: 10.1158/1535-7163.MCT-15-0282. Epub 2015 Sep 8.

9.

Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma.

Faria CC, Agnihotri S, Mack SC, Golbourn BJ, Diaz RJ, Olsen S, Bryant M, Bebenek M, Wang X, Bertrand KC, Kushida M, Head R, Clark I, Dirks P, Smith CA, Taylor MD, Rutka JT.

Oncotarget. 2015 Aug 28;6(25):21718-29.

10.

Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.

Diaz RJ, Golbourn B, Faria C, Picard D, Shih D, Raynaud D, Leadly M, MacKenzie D, Bryant M, Bebenek M, Smith CA, Taylor MD, Huang A, Rutka JT.

Oncotarget. 2015 Feb 20;6(5):3359-74.

11.

Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.

Faria CC, Golbourn BJ, Dubuc AM, Remke M, Diaz RJ, Agnihotri S, Luck A, Sabha N, Olsen S, Wu X, Garzia L, Ramaswamy V, Mack SC, Wang X, Leadley M, Reynaud D, Ermini L, Post M, Northcott PA, Pfister SM, Croul SE, Kool M, Korshunov A, Smith CA, Taylor MD, Rutka JT.

Cancer Res. 2015 Jan 1;75(1):134-46. doi: 10.1158/0008-5472.CAN-13-3629. Epub 2014 Nov 12.

12.

Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway.

Park JB, Agnihotri S, Golbourn B, Bertrand KC, Luck A, Sabha N, Smith CA, Byron S, Zadeh G, Croul S, Berens M, Rutka JT.

Oncotarget. 2014 Oct 15;5(19):9382-95.

13.

Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.

Barszczyk M, Buczkowicz P, Castelo-Branco P, Mack SC, Ramaswamy V, Mangerel J, Agnihotri S, Remke M, Golbourn B, Pajovic S, Elizabeth C, Yu M, Luu B, Morrison A, Adamski J, Nethery-Brokx K, Li XN, Van Meter T, Dirks PB, Rutka JT, Taylor MD, Tabori U, Hawkins C.

Acta Neuropathol. 2014 Dec;128(6):863-77. doi: 10.1007/s00401-014-1327-6. Epub 2014 Aug 6.

14.

ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents.

Agnihotri S, Burrell K, Buczkowicz P, Remke M, Golbourn B, Chornenkyy Y, Gajadhar A, Fernandez NA, Clarke ID, Barszczyk MS, Pajovic S, Ternamian C, Head R, Sabha N, Sobol RW, Taylor MD, Rutka JT, Jones C, Dirks PB, Zadeh G, Hawkins C.

Cancer Discov. 2014 Oct;4(10):1198-213. doi: 10.1158/2159-8290.CD-14-0157. Epub 2014 Aug 6.

15.

The role of drebrin in glioma migration and invasion.

Terakawa Y, Agnihotri S, Golbourn B, Nadi M, Sabha N, Smith CA, Croul SE, Rutka JT.

Exp Cell Res. 2013 Feb 15;319(4):517-28. doi: 10.1016/j.yexcr.2012.11.008. Epub 2012 Nov 29.

PMID:
23201135
16.

ECT2 and RASAL2 mediate mesenchymal-amoeboid transition in human astrocytoma cells.

Weeks A, Okolowsky N, Golbourn B, Ivanchuk S, Smith C, Rutka JT.

Am J Pathol. 2012 Aug;181(2):662-74. doi: 10.1016/j.ajpath.2012.04.011. Epub 2012 Jun 7.

PMID:
22683310
17.

Role of the cofilin activity cycle in astrocytoma migration and invasion.

Nagai S, Moreno O, Smith CA, Ivanchuk S, Romagnuolo R, Golbourn B, Weeks A, Seol HJ, Rutka JT.

Genes Cancer. 2011 Sep;2(9):859-69. doi: 10.1177/1947601911431839.

18.

Aurora kinase B/C inhibition impairs malignant glioma growth in vivo.

Diaz RJ, Golbourn B, Shekarforoush M, Smith CA, Rutka JT.

J Neurooncol. 2012 Jul;108(3):349-60. doi: 10.1007/s11060-012-0835-2. Epub 2012 Mar 1.

PMID:
22382783

Supplemental Content

Loading ...
Support Center